N/A
N=319
Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization
Cardiovascular Diseases · Coronary Disease · Heart Failure · Heart Failure, Congestive · Heart Diseases
Bottom Line
View on ClinicalTrials.gov: NCT00074724 ↗Enrolled (actual)
319
Serious AEs
—
Results posted
Apr 2021
Primary outcome: Primary: Survival Free of Cardiac Hospitalization
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Coronary Artery Bypass (Procedure); Modern medical management (Drug); Dobutamine echocardiography (Device); Optimal medical therapy (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medstar Health Research Institute
- Primary completion
- Dec 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Survival Free of Cardiac Hospitalization |
— | — |
| SECONDARY Left Ventricular Ejection Fraction |
— | — |
Summary
To define the role of the assessment of myocardial viability with dobutamine echocardiography (DE) in the clinical evaluation and selection of the best treatment for a high-risk subset of patients with coronary artery disease.
Eligibility Criteria
Enrollment Requirements
Inclusion Criteria
- Symptomatic heart failure defined as NYHA Class II - IV (within 3 months of entry)
- LV less than 35% defined by CMR or gated SPECT studies
- Coronary anatomy suitable for revascularization
Exclusion Criteria
- Primary valvular heart disease clearly defined indicating the need for valve repair or replacement
- Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support
- PCI planned for CAD treatment
- Acute myocardial infarction within 30 days
- More than one prior cardiac operation
- Non-cardiac illness with life expectancy of less than 3 years
- Non-cardiac illness imposing substantial operative mortality. Patients eligible to enter the study will be further evaluated by the STICH team for SVR eligibility.
Data sourced from ClinicalTrials.gov (NCT00074724). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.